The covert “C”: Prevalence, risk factors and management of hepatitis C in psychiatric inpatients

J Ramachandran, H Slattery, S Budd, T Mohan, T Cowain, A Baas, L Wigg, J Alexander, K Muller, R Woodman, B Kaambwa, A Wigg

Research output: Contribution to journalMeeting Abstract

Abstract

Background and Aims: Treatment of hepatitis C virus (HCV) in patients with mental illness has previously been hampered by the adverse neuropsychiatric effects of interferon therapy and difficulties in engaging with the patients using traditional treatment models. In addition, there is little Australian literature describing the prevalence of HCV in psychiatric populations. The new era of direct-acting antiviral (DAA) therapy has renewed interest in the treatment of HCV in this population. The aims of this study were therefore to assess HCV risk factors and prevalence in a large population of acute psychiatric inpatients and to explore treatment models of care.
Original languageEnglish
Pages (from-to)67-68
Number of pages2
JournalJournal of Hepatology
Volume68
Issue numberS1
DOIs
Publication statusPublished - Sept 2018
EventAustralian Gastroenterology Week 2018: Gut Matters - Brisbane Convention and Exhibition Centre, Brisbane, Australia
Duration: 8 Sept 201810 Sept 2018

Keywords

  • Hepatitis C
  • Psychiatric inpatients
  • Mental Illness
  • Treatment methods
  • Direct acting antiviral drugs

Fingerprint

Dive into the research topics of 'The covert “C”: Prevalence, risk factors and management of hepatitis C in psychiatric inpatients'. Together they form a unique fingerprint.

Cite this